Table 1 Characteristics of the subgroups of patients treated with either iloprost (n = 16) or bosentan (n = 11)
Characteristic | Iloprost | Bosentan |
|---|---|---|
lcSSc | 12 (75%) | 5 (45.5%) |
dcSSc | 2 (12.5%) | 5 (45.5%) |
Overlap | 2 (12.5%) | 1 (9%) |
CREST+ | 8 (50%) | 4 (36.4%) |
ANA+ | 14 (87.5%) | 11 (100%) |
ACA + (overlap excluded) | 5 (35.7%) | 3 (30%) |
Anti-Scl-70 (overlap excluded) | 5 (35.7%) | 4 (40%) |
Anti-CENP-B (overlap excluded) | 2 (14.3%) | 2 (20%) |
Anti-Ro/SS-A (overlap excluded) | 4 (28.6%) | 1 (10%) |
Anri-Ro/SS-B (overlap excluded) | 1 (7.1%) | 0 |
Anti-RNP (-Sm, -70) (overlap excluded) | 1 (7.1%) | 1 (10%) |